Ruthenium-based complex nanocarriers for cancer therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22357152.
- Also identified by DOI 10.1016/j.biomaterials.2012.01.057.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A new organometallic ruthenium complex, named AziRu, along with three amphiphilic nucleoside-based ruthenium complexes, ToThyRu, HoThyRu and DoHuRu, incorporating AziRu in their skeleton, have been synthesized, stabilized in POPC phospholipid formulations and studied for their antineoplastic activity. Self-aggregation behavior of these complexes was investigated, showing that the three synthesized AziRu derivatives able to form liposomes and, under specific conditions, elongated micelles. The formulations prepared in POPC proved to be stable for months and showed high in vitro antiproliferative activity. The here described results open new scenarios in the design of innovative transition metal-based supramolecular systems for anticancer drugs vectorization.
Medical subject headings
- Antineoplastic Agents
- Nanoparticles
- Neoplasms
- Organometallic Compounds
- Ruthenium